Keymed Biosciences Inc.
康諾亞生物醫藥科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2162)

VOLUNTARY ANNOUNCEMENT
PRIMARY STUDY ENDPOINTS FROM PHASE III CLINICAL TRIAL OF CM310 FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN ADULTS

This announcement is made by Keymed Biosciences Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The Company is pleased to announce that the Phase III confirmatory clinical study of its self-developed Class 1 innovative drug CM310 recombinant humanized monoclonal antibody injection in subjects with moderate to severe atopic dermatitis (AD) (trial protocol number: CM310AD005) has completed the data unblinding and preliminary statistical analyses, and both of the co-primary endpoints were achieved successfully. More details will be subsequently released in academic journals/academic conferences.

CM310AD005 is a multi-center, randomized, double-blind, placebo-controlled Phase III confirmatory clinical study to evaluate the efficacy, safety, PK/PD and immunogenicity of CM310 in subjects with moderate to severe atopic dermatitis. The eligible subjects were randomized in a 1:1 ratio to receive CM310 (600mg - 300mg Q2W) or placebo. The co-primary endpoints are the proportion of subjects with EASI-75 (Eczema Area and Severity Index (EASI) ≥75% improvement from baseline) and the proportion of subjects with IGA score of 0 or 1 and a reduction of ≥2 points from baseline at Week 16 of treatment.

The results showed that the co-primary endpoints of CM310 were achieved successfully, and the safety profiles were well and consistent with the historical results. The Group plans to submit for the marketing application of CM310 for the treatment of moderate to severe atopic dermatitis in adults, and communicate with the Center for Drug Evaluation of the National Medical Products Administration (the "**NMPA**") of the PRC in the near future.

About CM310

CM310 is a humanized and highly potent antagonist antibody against interleukin-4 receptor α-subunit (IL-4Rα). It is the first domestically-developed IL-4Rα antibody that received IND approval from the NMPA. By targeting IL-4Rα, CM310 can lead to dual-blockade of interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling. IL-4 and IL-13 are two critical cytokines for initiating type II inflammation. CM310 has demonstrated favorable safety and encouraging efficacy in various historical clinical trials.

Cautionary Statement as required by Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately develop, market and/or commercialize CM310 successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Keymed Biosciences Inc.
Dr. Bo CHEN
Chairman

Hong Kong, March 28, 2023

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Bo CHEN, Dr. Changyu WANG and Dr. Gang XU as executive Directors; Mr. Qi CHEN, Dr. Min Chuan WANG and Mr. Yilun LIU as non-executive Directors; Prof. Xiao-Fan WANG, Prof. Yang KE, Mr. Cheuk Kin Stephen LAW and Prof. Linqing LIU as independent non-executive Directors.